ORIC-613

ORIC-613 is an orally bioavailable, potent, and highly selective small molecule inhibitor of Polo-like kinase 4 (PLK4). It is being developed by ORIC Pharmaceuticals as a potential first- and best-in-class therapy for cancers characterized by high levels of TRIM37. The drug demonstrates synthetic lethality in tumor cells with elevated TRIM37 expression, particularly in breast cancer and neuroblastoma models. Preclinical studies have shown that ORIC-613 induces apoptotic tumor cell death specifically in TRIM37-high cells while sparing wildtype cells. It has also exhibited efficacy in breast cancer models resistant to CDK4/6 inhibitors and shows superior kinome selectivity compared to other PLK4 inhibitors such as CFI-400945 and RP-1664. As of April 2024, the highest development phase for ORIC-613 is preclinical, with ongoing research focused on breast cancer[1][2][3][5][6].

Other names

ORIC PLK4 inhibitor